FDA’s promotion of post-COVID plasma treatment was as bad as it appeared
FDA was selective with its numbers, and it used the wrong risk measure.
Full Article
FDA’s promotion of post-COVID plasma treatment was as bad as it appeared
Ars Technica
0 shares
1 views